Dicerna Pharmaceuticals (OTCMKTS:SLNCF) saw a large growth in short interest in August. As of August 31st, there was short interest totalling 3,800 shares, a growth of 52.0% from the August 15th total of 2,500 shares. Based on an average trading volume of 900 shares, the short-interest ratio is currently 4.2 days.

Separately, HC Wainwright initiated coverage on shares of Dicerna Pharmaceuticals in a report on Monday, August 24th. They set a “buy” rating for the company.

Shares of Dicerna Pharmaceuticals stock opened at $6.14 on Wednesday. Dicerna Pharmaceuticals has a 12-month low of $2.08 and a 12-month high of $7.70.

Dicerna Pharmaceuticals Company Profile

Silence Therapeutics plc focuses on the discovery, development, and delivery of novel RNA therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company designs short interfering RNA (siRNA) molecules that trigger the RNAi pathway and mediate the degradation of specific target messenger RNAs.

Further Reading: Why do company’s buyback their stock?

Receive News & Ratings for Dicerna Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.